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Abstract 
Medullary thyroid cancer (MTC) is a rare disease, often displaying an aggressive behavior and a poor 
prognosis. Serum calcitonin represents the most sensitive marker of MTC and its routine measurement in 
patients with thyroid nodules allows early detection of occult MTC and appropriate surgical cure.Here we 
report on a 55-yr-old woman with a long-standing goiter, autonomously functioning thyroid 
nodules and subclinical thyrotoxicosis, who was diagnosed with MTC at an early stage by means 
of calcitoninscreening. This rare case highlights the importance of performing routine calcitonin 
measurementin thyroid nodules. 
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Introduction 
Medullary thyroid cancer (MTC) is an uncommon malignancy arising from parafollicularCcells, 
accounting for about 5-10% of thyroid malignancy (1). MTC presents in sporadic (75-80%)and 
familial forms (20-25%, multiple endocrine neoplasia, MEN2A and MEN 2B, or familial MTC), the 
latter being secondary to germline mutations in the RET proto-oncogene (2). Compared to well-
differentiated thyroid cancers (DTC) arising from the follicular epithelium,MTC has a more 
aggressive behaviour and a lower rate of cure once the disease spreads beyond the thyroid (1,2). It 
has been estimated a 10-yearsurvival rateof about 50%, mostly depending on the stage of the tumour 
at diagnosis (2). Therefore, early diagnosis of MTC is paramount,but it still representsa challenge in 
clinical practice (2). 
The main clinical manifestation of MTC is a thyroid nodule, either single or in the context of a 
multinodular goitre (1,2). However, neither neck ultrasonography (US)nor fine needleaspiration 
biopsy (FNAB)achieve as highdiagnostic reliability in MTC as they have in DTC (3,4).  
Calcitonin (Ctn) secreted by parafollicular C cells represents a highly sensitive marker of MTC and 
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the measurement of serum Ctn levelsallows early diagnosis and curative surgery in most patients 
(5). However, there is no consensus on cost-effectiveness of routine Ctn screening in patients with 
thyroid nodules (6-8). 
Herein we present a 55-year-old woman with MTC detected at an early stage by means of Ctn 
screening during the diagnostic work-up of a long-standing multinodular goiter. 
Case Report 
A 55-year-old female patient was referred to our EndocrineUnit in 2016, because of 
recurrent atrial fibrillation (AF) and subclinical thyrotoxicosis. There was no family history 
of thyroid cancer. The patient had a long-standing multinodular goiterand was not taking 
any medications. Starting from 2014 she had suffered from recurrent AFs and serum TSH 
values had been found to be low or frankly suppressed, with free thyroid hormones levels 
within the normal range (subclinical thyrotoxicosis). A painlessmass in the right anterior 
side of theneck had appeared about one year earlier.Physical examination demonstrated an 
enlarged thyroid lobe with a palpable, nodular lesion in itslower part, moving with 
deglutition. Neck US demonstrated a 33-mm isoechoic nodule, with regular margins, a 
peripheral halo and colliquative areas, in the lower portion of the rightthyroid lobe, 
corresponding to the palpable mass. 
Also, a hypoechoid nodule, with regular margins, measuring 15x14x17 mm, was described 
in the upper portion of the right lobe, along with three sub-centimetric, isoechoid nodules in 
the left lobe (Figure 1, panels A-C).  Thyroidscintigraphy revealed an avid uptake of the 
tracer in the right lower lobe and in the left-sided nodules, with no uptake by the extra 
nodular tissue, consistently with autonomously functioning thyroid nodules (AFTNs) 
(Figure 1, panel D). 
US-guided FNAB of the right-upper“cold” nodule was performed, but cytological 
examination was inconclusive (TIR1).Hormonal profile confirmed suppressed serum TSH, 
with normal values of free triiodothyronine (FT3) and free thyroxine (FT4)(Table 1). 
Serum Ctn measurement was performed to screen for medullary thyroid cancer and was 
found to be high (Table 1). The patient refused to undergo intravenous calcium stimulation 
test, that could have been useful in distinguishing between MTC and a non-thyroidal 
malignancy secreting Ctn (i.e. an enteric or pulmonary neuroendocrine tumor) . Since serum 
Ctn was greater than 500 pg/mL, pre-operativesystemic imaging (total-body contrast-
enhanced computed tomography, TCT) was performed, in addition to neck US; no regional 
or distant metastases were detected. 
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Figure 1. Thyroid ultranonography and scintigraphy of our patient: illustrative images. 
 
 
 
The presence of a pheocromocitoma and/or primary hyperparathyroidism (pHPTH) wasalso 
excluded (Table 1). The patient underwent total thyroidectomy and central and 
lateralcompartment neck lymph node dissections. At pathology, the right-uppernodule was 
confirmed as anMTC, without vascular or capsular invasion (pT1aN0M0). All the excised 
lymph nodes (n=14) were negative. After surgery, serum Ctn dropped to 0.7 pg/ml and CEA 
to 0.5 ng/dl, and so they remained during the follow-up. No genetic alterations of the RET 
gene were found by sequencing of germline DNA from the patient. At the last control in our 
hospital, two years after surgery, the patient had noclinical, biochemical and instrumental 
evidence of recurrent or residual MTC. 
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Table 1. Main biochemical data of our patient at time of MTC diagnosis. 
 
 
 
 
 
*Patient’s values typed in bold are altered. 
Analyte (unit of measure) Patient’s value* Normal range 
Calcitonin ng/ml 1764 0-6.4 
CEAng/ml 5.5 0-5.0 
Chromogranin A ng/ml 19.2 <101.9 
TSH µIU/ml 0.08 0.27-4.20 
FT3 pg/ml 2.15 2-4.4 
FT4 pmol/L 18.7 12-22 
TPO-Ab NEG <10 
Tg-Ab NEG <100 
PTH pg/ml 29.90 8-76 
Calcium mg/dl 9.3 8.2-10.4 
Urinary ephinefrine µg/24h 9.5 1.7-22.4 
Urinary normetanephrineµg/24h 17.7 12.1-85.5 
Urinary metanephrineµg/24h 125 10-275 
Discussion 
The unusual case of this 55-yr-old woman demonstrates the importance of routine measurement 
of Ctn to detect occult MTC in patients harboring thyroid nodules. In our patient, there were no 
clues to suspect malignancy preoperatively. She had no family history of thyroid cancer or 
personal risk factors, except for the multinodular goiter, which represents itself a modifiable risk 
factor. The clinical presentation was mainly characterized by the presence of recurrent AF, 
subclinical thyrotoxicosis and AFTNs in the context of a longstanding multinodular goiter, a quite 
common and reassuring clinical picture. To the best of our knowledge, this is the second report of 
such an association of MTC and AFTNs with subclinical thyrotoxicosis. Prior of us, Pacini et al. 
reported an unique case of unsuspected MTC in a patient harboring an AFTN in the same lobe, 
among a large unselected series of patients with nodular thyroid disease (9).In our patient, US did 
not reveal features of suspected malignancy: the nodule was hypoechoic, but its margins were 
regular and there were no other US signs of malignancy (taller than wide shape, 
microcalcifications, intra-nodular vascularity, …) or lymph nodal involvement. 
The present case emphasizes how US, that represent the main tool for evaluation and risk 
stratification of thyroid nodules, isoften unable to suspect/diagnose MTC preoperatively.Despite 
hypoechoic lesions have a higher risk of being malignant, hypoechogenicity alone is inaccurate in 
predicting malignancy. Moreover, most of studies evaluating US criteria of malignancy concern 
papillary thyroid carcinoma (PTC), that represents the most common histotype of thyroid cancer, 
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while only few studies are available on US criteria for possibly malignant MTC. From these 
studies it emerges that a not negligible proportion of MTC do not fit the “classic” US criteria of 
malignancy: at least, one outof four MTC nodules appears not suspicious on US (i.e., iso-echoid 
nodule, mixed or spongiform aspect, regular margins, no microcalcifications) (2,3). Trimboli and 
co-workers showed low frequency of USfeatures associated to PTC when analysed in MTC. 
Furthermore, the presence of one US risk feature (as in our patient) was almost equal in MTC 
(58.3%) and benign lesions (55.5%), while it was significantly (p<0.001) more frequent in PTC 
(3). Moreover, even when the suspicious nodule is submitted to FNAB, cytology has several 
pitfalls for MTC and is often non diagnostic (as in our case), with a reported sensitivity of no 
more than 63% (3,4). 
Serum Ctn measurement represents the most sensitive tool for pre-operative diagnosis of MTC, 
much more sensitive than cytology(5, 9).Given the above discussed diagnostic limits of US, it is 
quite hard to propose serum Ctn measurement in selected patients; it should be rather performed 
in all patients with thyroid nodules. Indeed, routine measurement of Ctnin thyroid nodules allows 
pre-operative detection of MTC at an early stage and appropriate surgical approach, including total 
thyroidectomy and lymph node dissection, with a favourable impact on tumour outcome and 
prognosis (2,5, 9).However, the cost-effectiveness of a universal screening approach is still a matter of 
debate, due to the very low prevalence of MTC (0.3-1.4%) among patients with thyroid nodules (6). 
Moreover, false-positive Ctn results exist and non MTC-related causes of high Ctn should be 
recognized and excluded: chronicrenal failure, heterophilic antibodies,HPTH, autoimmunethyroiditis, 
mastocytosis, and various non-thyroid tumors, including small cell and large cell lung cancers, 
prostatecancer, enteric and pulmonary neuroendocrinetumors(5, 8).Thus, evaluating the cost-benefit 
ratio, a universal screening for Ctndefinitively improves the preoperative diagnosis of often 
unsuspected MTC and the initial surgical approach, achieving a high rate of definite cure. On the 
other hand, a larger number of subjects with abnormal serum Ctnlevels who have no MTC would 
undergo unnecessary surgery, with its possible complications and the need of life-long L-thyroxine 
therapy.  Also, the low specificity of assays for measuring Ctnshould be taken into account: a negative 
test does not rule out disease (5, 8).  For these reasons, recent ATA guidelines (6) do not recommend 
either for or against routine measurement of Ctn, while the AACE/AME/ETA guidelines (7) suggests 
Ctn in the routine workup of thyroid nodules. The ATA guidelines for MTC management (8) 
recommend“that physicians decide whether the technique is useful in the management of patients in 
their clinic (Recommendation20)”. 
Although anedoctal, the present case highlights the importance of considering MTC in the 
APMB - Atti della Accademia Peloritana dei Pericolanti 
Classe di Scienze Medico Biologiche 
Vol. 106(2) 2018 
 
ISSN 1828-6550 
 
 
DOI: 10.6092 / 1828-6550 / APMB.106.2.2018.A1 
 
APMB - Atti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche (2018), 106(2):A1(1-6)  
DOI:10.6092 / 1828-6550 / APMB.106.2.2018.A1 
differential diagnosis of thyroid nodules bymeans of Ctn screening. 
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